Chinese pharmaceutical companies are performing very well. However, they need to evolve to remain competitive. Analysis of the top 50 listed drugmakers in China and Hong Kong determined the following metrics: In 2010, the average revenue growth was 27%, while net income rose by 37%. The combined market capitalisation was US$135bn, which equates to one… [Read more]

BMI believes the commercial success of the pharmaceutical industry depends on innovation to a much greater extent than any other industry. The long-term success of the sector is highly dependent on maintaining a steady rate of new product launches, to replace older products with expired patents and recover revenues lost to the generic drug sector…. [Read more]

Risk Watchdog believes that drug repositioning will become more common, especially if the number of new molecular entities (NMEs) approved each year continues to drop. Multinational drugmakers are looking to maintain revenues during the patent cliff and efficiencies are being sought in research units. By identifying new uses for established and investigational medicines, pharmaceutical companies… [Read more]

“If you have a lot of what people want and can’t get, then you can supply the demand and shovel in the dough”. – Lucky Luciano It’s a simple enough concept, and one that helped make the father of modern organised crime in the United States cited above ‘one of the most influential builders and… [Read more]

Please consider ‘Mexico eases drug possession law’: The Mexican government has enacted a law decriminalising the possession of small amounts of drugs, including cocaine and heroin. Mexican prosecutors say the move does not amount to legalisation. They say it is designed to prevent corrupt police from seeking bribes from small-time drug users, and to encourage… [Read more]